Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR…
AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease Presenter: Arnold Bakker, Ph.D., Johns Hopkins University Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher Poster Presentation Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and…
HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics Richard Mohs 1 , Sharon Rosenzweig-Lipson 1 , Arnold Bakker2 , Elizabeth Chang2 , Nisha Rani2 ,…
Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”
Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The Hope4MCI Trial
– Topline results expected in November 2022 BALTIMORE, April 21, 2021 — AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s…
AGB101 to Slow the Progression of MCI in Alzheimer’s Disease
HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101
